한빛사논문
- 조회390
Seungju Yang 1, San Hae Im 1, Ju Yeon Chung 1, Juhee Lee 1, Kyung-Hun Lee 2 3, Yoo Kyung Kang 4 and Hyun Jung Chung 1 *
1Department of Biological SciencesKorea Advanced Institute of Science and TechnologyDaejeon 34141, Republic of Korea
2Department of Internal Medicine Seoul National University Hospital Seoul 03080, Republic of Korea
3Cancer Research Institute Seoul National University Seoul 03080, Republic of Korea
4College of Pharmacy Gyeongsang National University Jinju 52828, Republic of Korea
*Corresponding author: correspondence to Hyun Jung Chung
Abstract
The CRISPR/Cas system has been introduced as an innovative tool for therapy, however achieving specific delivery to the target has been a major challenge. Here, an antibody-CRISPR/Cas conjugate platform that enables specific delivery and target gene editing in HER2-positive cancer is introduced. The CRISPR/Cas system by replacing specific residues of Cas9 with an unnatural amino acid is engineered, that can be complexed with a nanocarrier and bioorthogonally functionalized with a monoclonal antibody targeting HER2. The resultant antibody-conjugated CRISPR/Cas nanocomplexes can be specifically delivered and induce gene editing in HER2-positive cancer cells in vitro. It is demonstrated that the in vivo delivery of the antibody-CRISPR/Cas nanocomplexes can effectively disrupt the plk1 gene in HER2-positive ovarian cancer, resulting in substantial suppression of tumor growth. The current study presents a useful therapeutic platform for antibody-mediated delivery of CRISPR/Cas for the treatment of various cancers and genetic diseases.
논문정보
- Research article
- 2024년 03월 (BRIC 등록일 2024-04-08)
- 국내 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
관련 보도자료
- Bio통신원
- 2024. 04. 08
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
